Retraction: Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX
Oncotarget. 2024 Feb 5;15:90. doi: 10.18632/oncotarget.28462.NO ABSTRACTPMID:38329724 | PMC:PMC10852066 | DOI:10.18632/oncotarget.28462 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Huan Liu Guizhi Zhou Xin Fu Haiyan Cui Guangrui Pu Yao Xiao Wei Sun Xinhua Dong Libin Zhang Sijia Cao Guiqin Li Xiaowei Wu Xu Yang Source Type: research
Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis
Oncotarget. 2024 Feb 5;15:91-103. doi: 10.18632/oncotarget.28512.ABSTRACTAbout 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known for its lowest survival rates among all oncological diseases and heterogenic molecular profile. Enormous amount of genetic changes, including somatic mutations, exceeds the limits of routine clinical genetic laboratory tests and further stagnates the development of personalized treatments. We aimed to build a mutational landscape of PCa in the Russian population based on full exome next-generation sequencing (NGS) of the limited group of patients. Applying a machine lear...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: P A Shatalov N A Falaleeva E A Bykova D O Korostin V A Belova A A Zabolotneva A P Shinkarkina A Yu Gorbachev M B Potievskiy V S Surkova Zh V Khailova N A Kulemin Denis Baranovskii A A Kostin A D Kaprin P V Shegai Source Type: research
GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells
Oncotarget. 2024 Feb 8;15:124-133. doi: 10.18632/oncotarget.28557.ABSTRACTGZ17-6.02, composed of curcumin, harmine and isovanillin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with an RP2D of 375 mg PO BID. The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not been studied. GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells. All three components are necessary for optimal killing of MF cells. GZ17-6.02 activated ATM, the AMPK, NFκB and PERK and inactivated ERK1/2, AKT, ULK1, ...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Michael R Booth Laurence Booth Jane L Roberts Cameron West Paul Dent Source Type: research
Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Oncotarget. 2024 Feb 5;15:104-105. doi: 10.18632/oncotarget.28536.NO ABSTRACTPMID:38329729 | PMC:PMC10852055 | DOI:10.18632/oncotarget.28536 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Yunfei Liao Lulu Chen Yong Feng Jacson Shen Yan Gao Gregory Cote Edwin Choy David Harmon Henry Mankin Francis Hornicek Zhenfeng Duan Source Type: research
Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland
In conclusion, NTRK gene fusion is infrequent in patients with PTC. Linkage of biobank samples to EHRs is feasible in describing the characteristics and outcomes of patients with PTC and potentially other cancer types.PMID:38329731 | PMC:PMC10852057 | DOI:10.18632/oncotarget.28555 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Wei Zhang Arndt A Schmitz Roosa E Kallionp ää Merja Per älä Niina Pitk änen Mikko Tukiainen Erika Alanne Korinna J öhrens Renate Schulze-Rath Bahman Farahmand Jihong Zong Source Type: research
Combining causal and correlative approaches to discover biomarkers of response to paclitaxel
Oncotarget. 2024 Feb 8;15:117-122. doi: 10.18632/oncotarget.28549.ABSTRACTWe recently discovered a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment. To further evaluate the potential application of this biomarker in the clinic for patients with glioblastoma, a prospective validation in cohorts of patients with glioblastoma is essential and will be performed as part of our ongoing phase II clinical trial (NCT04528680). The val...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Alberto Moscona-Nissan Karl J Habashy Victor A Arrieta Adam M Sonabend Crismita Dmello Source Type: research
Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1 α inhibition, and hypoxia-activated chemotherapy
Oncotarget. 2024 Feb 8;15:123. doi: 10.18632/oncotarget.28560.NO ABSTRACTPMID:38329733 | PMC:PMC10852056 | DOI:10.18632/oncotarget.28560 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Changhwan Yoon Kevin K Chang Jun Ho Lee William D Tap Charles P Hart M Celeste Simon Sam S Yoon Source Type: research
Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
Oncotarget. 2024 Feb 5;15:65-75. doi: 10.18632/oncotarget.28547.ABSTRACTMultiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy. These new drugs have often been evaluated together and in combination with older agents. However, even these novel combinations eventually become ineffective; and, thus, novel therapeutic approaches are necessary to help overcome resistance to these treatments. Recently, the ...
Source: Oncotarget - February 6, 2024 Category: Cancer & Oncology Authors: Ashley Del Dosso Elizabeth Tadevosyan James R Berenson Source Type: research
BCAS1 defines a heterogeneous cell population in diffuse gliomas
This study analyzes the expression of BCAS1 in different tumor samples from patients with diffuse gliomas (17 oligodendrogliomas; 8 astrocytomas; 60 glioblastomas) and uncovers the molecular and ultrastructural features of BCAS1+ cells by immunostaining and electron microscopy. Our results show that BCAS1+ cells exhibit stellate or spherical morphology with similar ultrastructural features. Stellate and spherical cells were detected as isolated cells in all studied gliomas. Nevertheless, only stellate cells were found to be proliferative and formed tightly packed nodules with a highly proliferative rate in oligodendrogliom...
Source: Oncotarget - January 26, 2024 Category: Cancer & Oncology Authors: Raquel Morales-Gallel Mar ía José Ulloa-Navas Patricia Garc ía-Tárraga Ricardo Prat-Ac ín Gaspar Reyn és Pedro P érez-Borredá Luis Rubio Vivian Capilla-Gonz ález Jaime Ferrer-Lozano Jos é Manuel García-Verdugo Source Type: research
The fate of drug discovery in academia; dumping in the publication landfill?
Oncotarget. 2024 Jan 24;15:31-34. doi: 10.18632/oncotarget.28552.NO ABSTRACTPMID:38275290 | PMC:PMC10812233 | DOI:10.18632/oncotarget.28552 (Source: Oncotarget)
Source: Oncotarget - January 26, 2024 Category: Cancer & Oncology Authors: Uzma Saqib Isaac S Demaree Alexander G Obukhov Mirza S Baig Amiram Ariel Krishnan Hajela Source Type: research
Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation
Oncotarget. 2024 Jan 24;15:36-48. doi: 10.18632/oncotarget.28544.ABSTRACTA subset of thyroid cancers present at advanced stage or with dedifferentiated histology and have limited response to standard therapy. Tumors harboring the BRAF V600E mutation may be treated with BRAF inhibitors; however, tumor response is often short lived due to multiple compensatory resistance mechanisms. One mode of resistance is the transition to an alternative cell state, which on rare occasions can correspond to tumor dedifferentiation. DNA sequencing and RNA expression profiling show that thyroid tumors that dedifferentiate after BRAF inhibit...
Source: Oncotarget - January 26, 2024 Category: Cancer & Oncology Authors: Mark Lee Luc Gt Morris Source Type: research
Retraction: Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice
Oncotarget. 2024 Jan 24;15:35. doi: 10.18632/oncotarget.28532.NO ABSTRACTPMID:38275293 | PMC:PMC10812234 | DOI:10.18632/oncotarget.28532 (Source: Oncotarget)
Source: Oncotarget - January 26, 2024 Category: Cancer & Oncology Authors: Fariba Poosti Ruchi Bansal Saleh Yazdani Jai Prakash Leonie Beljaars Jacob van den Born Martin H de Borst Harry van Goor Jan-Luuk Hillebrands Klaas Poelstra Source Type: research
Retraction: Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma
Oncotarget. 2024 Jan 16;15:19. doi: 10.18632/oncotarget.28366.NO ABSTRACTPMID:38227736 | PMC:PMC10791073 | DOI:10.18632/oncotarget.28366 (Source: Oncotarget)
Source: Oncotarget - January 16, 2024 Category: Cancer & Oncology Authors: Sijie Cheng Tieling Li Cheng Wang Keyu Wang Chengcai Lai Jin Yan Hongxia Fan Fang Sun Zhaohai Wang Peirui Zhang Linxiang Yu Zhixian Hong Guanglin Lei Baijun Sun Yuan Gao Zhaohui Xiao Xu Ji Ruilan Wang Jianzhong Wu Xiliang Wang Shaogeng Zhang Penghui Yang Source Type: research
Lazarus effect in a patient initially empirically treated with osimertinib for < em > EGFR < /em > L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report
In this report, we present a patient of East Asian descent whose initial presentation included severe, progressive leptomeningeal carcinomatosis and a small lung mass, with limited tissue available for molecular testing. She responded to empiric, urgent initiation of osimertinib, repeat tissue sampling revealed an EGFR L858R mutation, and she has experienced durable disease improvement for 18 months on osimertinib monotherapy.PMID:38227738 | PMC:PMC10791074 | DOI:10.18632/oncotarget.28550 (Source: Oncotarget)
Source: Oncotarget - January 16, 2024 Category: Cancer & Oncology Authors: Shreya Bhatia Manuel G Cortez Spencer Lessans Wade T Iams Source Type: research
Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma
Oncotarget. 2024 Jan 16;15:20-26. doi: 10.18632/oncotarget.28548.ABSTRACTMultiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in the bone marrow. In spite of recent advances in the field of MM, the disease has remained incurable. MM is preceded by a premalignant state known as monoclonal gammopathy of undetermined significance (MGUS), with a risk of progression to MM of 1% per year. Establishing a scalable approach that refines the identification of MGUS patients at high risk of progression to MM can transform the clinical management of ...
Source: Oncotarget - January 16, 2024 Category: Cancer & Oncology Authors: Bilal M El-Masri Benedeta Leka Fatima Mustapha Michael Tveden Gundesen Maja Hinge Thomas Lund Thomas L Andersen Marta Diaz-delCastillo Abbas Jafari Source Type: research
